(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.
The three biggest winners today are Aravive, Senmiao Technology Limited, and Amicus Therapeutics.
| Rank | Financial Asset | Price | Change | Updated (EST) |
|---|---|---|---|---|
| 1 | Aravive (ARAV) | 0.21 | 45.67% | 2023-10-20 10:41:06 |
| 2 | Senmiao Technology Limited (AIHS) | 0.44 | 9.5% | 2023-10-20 03:14:05 |
| 3 | Amicus Therapeutics (FOLD) | 11.01 | 6.95% | 2023-10-20 12:12:26 |
| 4 | Acer Therapeutics (ACER) | 0.85 | 5.08% | 2023-10-19 23:48:05 |
| 5 | Aethlon Medical (AEMD) | 1.49 | 4.93% | 2023-10-20 01:17:04 |
| 6 | Genmab (GMAB) | 29.93 | 4.47% | 2023-10-20 12:16:29 |
| 7 | U.S. Gold Corp (USAU) | 3.48 | 4.02% | 2023-10-20 12:17:46 |
| 8 | FibroGen (FGEN) | 0.60 | 3.92% | 2023-10-20 12:12:13 |
| 9 | Inovio Pharmaceuticals (INO) | 0.47 | 3.78% | 2023-10-20 12:13:06 |
| 10 | Winmark Corporation (WINA) | 419.33 | 3.76% | 2023-10-19 19:42:05 |
The three biggest losers today are AGBA Acquisition Limited, Artelo Biosciences, and Arcutis Biotherapeutics.
| Rank | Financial Asset | Price | Change | Updated (EST) |
|---|---|---|---|---|
| 1 | AGBA Acquisition Limited (AGBAW) | 0.01 | -24.67% | 2023-10-20 03:06:05 |
| 2 | Artelo Biosciences (ARTLW) | 0.03 | -19.75% | 2023-10-20 11:08:05 |
| 3 | Arcutis Biotherapeutics (ARQT) | 2.44 | -19.47% | 2023-10-20 11:06:05 |
| 4 | Aprea Therapeutics (APRE) | 4.14 | -16.53% | 2023-10-20 09:13:05 |
| 5 | Enphase Energy (ENPH) | 99.67 | -14% | 2023-10-20 12:11:56 |
| 6 | Wheeler Real Estate Investment Trust (WHLR) | 0.99 | -12.38% | 2023-10-19 19:15:05 |
| 7 | Adverum Biotechnologies (ADVM) | 0.89 | -12.08% | 2023-10-20 01:14:04 |
| 8 | Regions Financial Corporation (RF) | 14.60 | -11.39% | 2023-10-20 12:21:55 |
| 9 | XTL Biopharmaceuticals Ltd. (XTLB) | 0.90 | -9.85% | 2023-10-19 22:43:05 |
| 10 | Zions Bancorporation N.A. (ZION) | 32.24 | -9.67% | 2023-10-19 23:10:05 |
Winners today
1. Aravive (ARAV) – 45.67%
Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases. Its lead product candidate is AVB-500, a decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase Ib/II clinical trial for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the treatment of clear cell renal cell carcinoma, HER negative breast cancer, uterine, pancreatic cancer, urothelial, and non-small-cell lung cancers. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a strategic collaboration agreement with WuXi Biologics to develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain AVB-500 as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. is headquartered in Houston, Texas.
NASDAQ ended the session with Aravive jumping 45.67% to $0.21 on Friday, after two sequential sessions in a row of losses. NASDAQ slid 1.53% to $12,983.81, after three sequential sessions in a row of losses, on what was an all-around down trend trading session today.
Earnings Per Share
As for profitability, Aravive has a trailing twelve months EPS of $-1.3.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -1497.43%.
Moving Average
Aravive’s worth is way higher than its 50-day moving average of $0.15 and way under its 200-day moving average of $1.29.
Sales Growth
Aravive’s sales growth is negative 74.2% for the present quarter and negative 72.9% for the next.
Yearly Top and Bottom Value
Aravive’s stock is valued at $0.21 at 17:32 EST, way under its 52-week high of $2.46 and way higher than its 52-week low of $0.11.
Revenue Growth
Year-on-year quarterly revenue growth declined by 21.1%, now sitting on 9.19M for the twelve trailing months.
More news about Aravive.
2. Senmiao Technology Limited (AIHS) – 9.5%
Senmiao Technology Limited engages in the automobile transaction and related services business in the People's Republic of China. Its services include the facilitation of automobile transaction and financing, connecting ride-hailing drivers to financial institutions to buy, or get financing on the purchase of, cars to be used to provide ride-hailing services. The company is also involved in the sale of automobiles; and provision of auto finance services. Senmiao Technology has strategic cooperation with Gaode Map for utilization in ride sharing initiatives. Senmiao Technology Limited was incorporated in 2017 and is based in Chengdu, the People's Republic of China.
NASDAQ ended the session with Senmiao Technology Limited rising 9.5% to $0.44 on Friday while NASDAQ slid 1.53% to $12,983.81.
Earnings Per Share
As for profitability, Senmiao Technology Limited has a trailing twelve months EPS of $-0.54.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -43.54%.
Yearly Top and Bottom Value
Senmiao Technology Limited’s stock is valued at $0.44 at 17:32 EST, way under its 52-week high of $1.12 and way above its 52-week low of $0.37.
Moving Average
Senmiao Technology Limited’s worth is under its 50-day moving average of $0.47 and way below its 200-day moving average of $0.72.
Volume
Today’s last reported volume for Senmiao Technology Limited is 325 which is 97.91% below its average volume of 15554.
More news about Senmiao Technology Limited.
3. Amicus Therapeutics (FOLD) – 6.95%
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. The company also develops AT-GAA, a novel treatment paradigm for Pompe disease; and enzyme replacement therapies for Pompe diseases. It has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. The company was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.
NASDAQ ended the session with Amicus Therapeutics rising 6.95% to $11.01 on Friday, after two successive sessions in a row of losses. NASDAQ dropped 1.53% to $12,983.81, after three successive sessions in a row of losses, on what was an all-around bearish trend trading session today.
Earnings Per Share
As for profitability, Amicus Therapeutics has a trailing twelve months EPS of $-0.62.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -130.04%.
Volatility
Amicus Therapeutics’s last week, last month’s, and last quarter’s current intraday variation average was a positive 0.67%, a negative 0.80%, and a positive 2.14%.
Amicus Therapeutics’s highest amplitude of average volatility was 1.48% (last week), 2.99% (last month), and 2.14% (last quarter).
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 41.7% and 73.7%, respectively.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Amicus Therapeutics’s EBITDA is -146.77.
Revenue Growth
Year-on-year quarterly revenue growth grew by 17.1%, now sitting on 350.56M for the twelve trailing months.
More news about Amicus Therapeutics.
4. Acer Therapeutics (ACER) – 5.08%
Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes four clinical-stage candidates: EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease; ACER-801 (osanetant) for the treatment of induced Vasomotor Symptoms; and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19. The company has a research collaboration agreement with the National Center for Advancing Translational Sciences (NCATS) to develop emetine hydrochloride as a potential treatment for patients with COVID-19; and a license agreement with Sanofi to acquire worldwide rights to osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist. Acer Therapeutics Inc. was founded in 1991 and is headquartered in Newton, Massachusetts.
NASDAQ ended the session with Acer Therapeutics jumping 5.08% to $0.85 on Friday while NASDAQ slid 1.53% to $12,983.81.
Earnings Per Share
As for profitability, Acer Therapeutics has a trailing twelve months EPS of $-2.03.
Yearly Top and Bottom Value
Acer Therapeutics’s stock is valued at $0.85 at 17:32 EST, way below its 52-week high of $4.56 and way higher than its 52-week low of $0.55.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 61.3% and 87%, respectively.
Moving Average
Acer Therapeutics’s value is higher than its 50-day moving average of $0.80 and way under its 200-day moving average of $1.19.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Acer Therapeutics’s EBITDA is -10.48.
More news about Acer Therapeutics.
5. Aethlon Medical (AEMD) – 4.93%
Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system. It is also developing TauSome, an exosomal biomarker candidate to diagnose chronic traumatic encephalopathy in living individuals. Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh Medical Center Hillman Cancer Center for studies related to head and neck cancer. The company was founded in 1999 and is based in San Diego, California.
NASDAQ ended the session with Aethlon Medical rising 4.93% to $1.49 on Friday while NASDAQ slid 1.53% to $12,983.81.
Earnings Per Share
As for profitability, Aethlon Medical has a trailing twelve months EPS of $-5.59.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -88.52%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Aethlon Medical’s EBITDA is 1.29.
Growth Estimates Quarters
The company’s growth estimates for the present quarter is 22.2% and a drop 16.7% for the next.
Yearly Top and Bottom Value
Aethlon Medical’s stock is valued at $1.49 at 17:32 EST, way under its 52-week high of $8.70 and above its 52-week low of $1.40.
More news about Aethlon Medical.
6. Genmab (GMAB) – 4.47%
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company also develops Teclistamab, which is in Phase 2 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
NASDAQ ended the session with Genmab jumping 4.47% to $29.93 on Friday, after three sequential sessions in a row of losses. NASDAQ dropped 1.53% to $12,983.81, after three sequential sessions in a row of losses, on what was an all-around negative trend trading session today.
Earnings Per Share
As for profitability, Genmab has a trailing twelve months EPS of $1.02.
PE Ratio
Genmab has a trailing twelve months price to earnings ratio of 29.34. Meaning, the purchaser of the share is investing $29.34 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17.84%.
Moving Average
Genmab’s worth is way below its 50-day moving average of $36.66 and way below its 200-day moving average of $38.63.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter and the next is 460.4% and 2475%, respectively.
Volume
Today’s last reported volume for Genmab is 951146 which is 58.1% above its average volume of 601604.
More news about Genmab.
7. U.S. Gold Corp (USAU) – 4.02%
U.S. Gold Corp. engages in the exploration and development of gold and precious metals in the United States. It also explores for copper and silver deposits. The company holds 100% interests in the CK Gold project, which consists of various mining leases and other mineral rights covering approximately 1,120 acres in Laramie County, Wyoming; the Keystone project that consists of 601 unpatented lode mining claims covering approximately 20 square miles in Eureka County, Nevada; and the Challis Gold project, which consists of 77 unpatented lode mining claims covering approximately 1,710 acres in Lemhi County, Idaho. It also has earn-in agreement to acquire a 50% ownership interest in the Maggie Creek project located in Eureka County, Nevada. The company was formerly known as Dataram Corporation and changed its name to U.S. Gold Corp. in June 2017. U.S. Gold Corp. is based in Elko, Nevada.
NASDAQ ended the session with U.S. Gold Corp jumping 4.02% to $3.48 on Friday while NASDAQ dropped 1.53% to $12,983.81.
Earnings Per Share
As for profitability, U.S. Gold Corp has a trailing twelve months EPS of $-0.97.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -45%.
Yearly Top and Bottom Value
U.S. Gold Corp’s stock is valued at $3.48 at 17:32 EST, way below its 52-week high of $7.48 and way higher than its 52-week low of $2.92.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, U.S. Gold Corp’s stock is considered to be overbought (>=80).
Volatility
U.S. Gold Corp’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.15%, a negative 0.40%, and a positive 2.41%.
U.S. Gold Corp’s highest amplitude of average volatility was 5.84% (last week), 3.16% (last month), and 2.41% (last quarter).
More news about U.S. Gold Corp.
8. FibroGen (FGEN) – 3.92%
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and Duchenne muscular dystrophy; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
NASDAQ ended the session with FibroGen rising 3.92% to $0.60 on Friday, after two sequential sessions in a row of losses. NASDAQ dropped 1.53% to $12,983.81, after three successive sessions in a row of losses, on what was an all-around negative trend trading session today.
Earnings Per Share
As for profitability, FibroGen has a trailing twelve months EPS of $-3.39.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -1015.79%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 48.7%, now sitting on 130.58M for the twelve trailing months.
More news about FibroGen.
9. Inovio Pharmaceuticals (INO) – 3.78%
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia, including cervical, vulvar, and anal dysplasia and is under phase II/III clinical trials; INO-3107 for HPV-related recurrent respiratory rapillomatosis and is under Phase 1/2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under phase 1b trial; and INO-4500 vaccine for lassa fever, which is under phase 1b trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.
NASDAQ ended the session with Inovio Pharmaceuticals jumping 3.78% to $0.47 on Friday while NASDAQ slid 1.53% to $12,983.81.
Earnings Per Share
As for profitability, Inovio Pharmaceuticals has a trailing twelve months EPS of $-0.63.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -72.13%.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Inovio Pharmaceuticals’s stock is considered to be overbought (>=80).
More news about Inovio Pharmaceuticals.
10. Winmark Corporation (WINA) – 3.76%
Winmark Corporation operates as a franchisor of five retail store concepts that buy, sell, trade, and consign used merchandise primarily in the United States and Canada. The company operates through two segments, Franchising and Leasing. Its franchises retail stores operate under the Plato's Closet, Once Upon A Child, Play It Again Sports, Style Encore, and Music Go Round brand names. The company's Plato's Closet brand stores buys and sells used clothing and accessories for the teenage and young adult market; and Once Upon A Child brand stores buys and sells used and new children's clothing, toys, furniture, equipment, and accessories primarily to parents of children ages infant to 12 years. Its Play It Again Sports brand stores buys, sells, trades in, and consigns used and new sporting goods, equipment, and accessories for various athletic activities, such as team sports, fitness, ski/snowboard, golf, and others; Style Encore brand stores buys and sells used women's apparel, shoes, and accessories; and Music Go Round brand stores buys, sells, trades in, and consigns used and new musical instruments, speakers, amplifiers, music-related electronics, and related accessories. In addition, the company is also involved in the middle-market equipment leasing business focusing on technology and business-essential equipment for large and medium-sized businesses. As of December 26, 2020, it had 1,264 franchised stores, as well as offers its products online at musicgoround.com, playitagainsports.com, and style-encore.com. Winmark Corporation was incorporated in 1988 and is headquartered in Minneapolis, Minnesota.
NASDAQ ended the session with Winmark Corporation rising 3.76% to $419.33 on Friday, after two successive sessions in a row of gains. NASDAQ fell 1.53% to $12,983.81, after three consecutive sessions in a row of losses, on what was an all-around bearish trend trading session today.
Earnings Per Share
As for profitability, Winmark Corporation has a trailing twelve months EPS of $11.11.
PE Ratio
Winmark Corporation has a trailing twelve months price to earnings ratio of 37.74. Meaning, the purchaser of the share is investing $37.74 for every dollar of annual earnings.
Yearly Top and Bottom Value
Winmark Corporation’s stock is valued at $419.33 at 17:32 EST, below its 52-week high of $419.42 and way higher than its 52-week low of $228.90.
More news about Winmark Corporation.
Losers Today
1. AGBA Acquisition Limited (AGBAW) – -24.67%
AGBA Group Holding Limited focuses on operating a full-service platform to banks, other financial institutions, brokers, and individual financial advisors to advise and serve its retail clients. The company offers a range of financial products, such as life insurance, pensions, property-casualty insurance, mutual funds, money lending, and real estate agency services. It also operates an health and wealth management platform that offers a range of services and value-added information in health, insurance, investments, and social sharing. The company is based in Wan Chai, Wan Chai.
NASDAQ ended the session with AGBA Acquisition Limited sliding 24.67% to $0.01 on Friday, after five sequential sessions in a row of losses. NASDAQ fell 1.53% to $12,983.81, after three consecutive sessions in a row of losses, on what was an all-around negative trend trading session today.
More news about AGBA Acquisition Limited.
2. Artelo Biosciences (ARTLW) – -19.75%
NASDAQ ended the session with Artelo Biosciences dropping 19.75% to $0.03 on Friday, after five consecutive sessions in a row of losses. NASDAQ fell 1.53% to $12,983.81, after three consecutive sessions in a row of losses, on what was an all-around down trend exchanging session today.
More news about Artelo Biosciences.
3. Arcutis Biotherapeutics (ARQT) – -19.47%
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
NASDAQ ended the session with Arcutis Biotherapeutics sliding 19.47% to $2.44 on Friday while NASDAQ fell 1.53% to $12,983.81.
Earnings Per Share
As for profitability, Arcutis Biotherapeutics has a trailing twelve months EPS of $-5.54.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -239.82%.
Yearly Top and Bottom Value
Arcutis Biotherapeutics’s stock is valued at $2.44 at 17:32 EST, way under its 52-week high of $20.11 and way higher than its 52-week low of $2.16.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 51.3% and 4.2%, respectively.
Volume
Today’s last reported volume for Arcutis Biotherapeutics is 13460500 which is 1061.14% above its average volume of 1159260.
More news about Arcutis Biotherapeutics.
4. Aprea Therapeutics (APRE) – -16.53%
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company's lead product candidate is APR-246 (Eprenetapopt), a small molecule p53 reactivator that is in late-stage clinical development for the treatment of hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia, as well as for relapsed/refractory TP53 mutant chronic lymphoid leukemia; and gastric, bladder, and non-small cell lung cancers. It also develops APR-548, a p53 reactivator that is on Phase I dose-escalation clinical trial for oral administration in MDS patients. The company was founded in 2006 and is headquartered in Boston, Massachusetts.
NASDAQ ended the session with Aprea Therapeutics sliding 16.53% to $4.14 on Friday while NASDAQ slid 1.53% to $12,983.81.
Earnings Per Share
As for profitability, Aprea Therapeutics has a trailing twelve months EPS of $23.58.
PE Ratio
Aprea Therapeutics has a trailing twelve months price to earnings ratio of 0.18. Meaning, the purchaser of the share is investing $0.18 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -48.87%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter is 51.7% and a drop 7.6% for the next.
More news about Aprea Therapeutics.
5. Enphase Energy (ENPH) – -14%
Enphase Energy, Inc., together with its subsidiaries, designs, develops, manufactures, and sells home energy solutions for the solar photovoltaic industry in the United States and internationally. The company offers semiconductor-based microinverter, which converts energy at the individual solar module level, and combines with its proprietary networking and software technologies to provide energy monitoring and control services. It also provides microinverter units and related accessories, an IQ gateway; IQ batteries; the cloud-based Enlighten monitoring service; storage solutions; and electric vehicle charging solutions; and design, proposal, permitting, and lead generation services. The company sells its solutions to solar distributors; and directly to large installers, original equipment manufacturers, strategic partners, and homeowners, as well as through its legacy product upgrade program or online store. Enphase Energy, Inc. was incorporated in 2006 and is headquartered in Fremont, California.
NASDAQ ended the session with Enphase Energy sliding 14% to $99.67 on Friday, after two sequential sessions in a row of losses. NASDAQ fell 1.53% to $12,983.81, after three successive sessions in a row of losses, on what was an all-around bearish trend trading session today.
Earnings Per Share
As for profitability, Enphase Energy has a trailing twelve months EPS of $3.56.
PE Ratio
Enphase Energy has a trailing twelve months price to earnings ratio of 28. Meaning, the purchaser of the share is investing $28 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 80.45%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is a negative 16.8% and a negative 21.9%, respectively.
Yearly Top and Bottom Value
Enphase Energy’s stock is valued at $99.67 at 17:32 EST, way below its 52-week low of $111.44.
Volume
Today’s last reported volume for Enphase Energy is 9718750 which is 157.35% above its average volume of 3776420.
Moving Average
Enphase Energy’s value is way below its 50-day moving average of $125.55 and way under its 200-day moving average of $177.42.
More news about Enphase Energy.
6. Wheeler Real Estate Investment Trust (WHLR) – -12.38%
Headquartered in Virginia Beach, VA, Wheeler Real Estate Investment Trust, Inc. (NASDAQ: WHLR ) is a fully integrated, self-managed commercial real estate investment company focused on owning and operating income-producing retail properties with a primary focus on grocery-anchored centers.
NASDAQ ended the session with Wheeler Real Estate Investment Trust dropping 12.38% to $0.99 on Friday, following the last session’s downward trend. NASDAQ slid 1.53% to $12,983.81, after three successive sessions in a row of losses, on what was an all-around bearish trend trading session today.
Earnings Per Share
As for profitability, Wheeler Real Estate Investment Trust has a trailing twelve months EPS of $-24.4.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -4.59%.
Yearly Top and Bottom Value
Wheeler Real Estate Investment Trust’s stock is valued at $0.99 at 17:32 EST, way under its 52-week high of $19.90 and way higher than its 52-week low of $0.82.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Mar 27, 2018, the estimated forward annual dividend rate is 1.36 and the estimated forward annual dividend yield is 27.09%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 60.8%, now sitting on 96.43M for the twelve trailing months.
More news about Wheeler Real Estate Investment Trust.
7. Adverum Biotechnologies (ADVM) – -12.08%
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal diseases, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
NASDAQ ended the session with Adverum Biotechnologies falling 12.08% to $0.89 on Friday while NASDAQ fell 1.53% to $12,983.81.
Earnings Per Share
As for profitability, Adverum Biotechnologies has a trailing twelve months EPS of $-1.26.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -71.11%.
Volume
Today’s last reported volume for Adverum Biotechnologies is 155525 which is 48.77% below its average volume of 303587.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Adverum Biotechnologies’s EBITDA is -2.98.
Yearly Top and Bottom Value
Adverum Biotechnologies’s stock is valued at $0.89 at 17:32 EST, way under its 52-week high of $2.34 and way higher than its 52-week low of $0.53.
More news about Adverum Biotechnologies.
8. Regions Financial Corporation (RF) – -11.39%
Regions Financial Corporation, a financial holding company, provides banking and bank-related services to individual and corporate customers. It operates through three segments: Corporate Bank, Consumer Bank, and Wealth Management. The Corporate Bank segment offers commercial banking services, such as commercial and industrial, commercial real estate, and investor real estate lending; equipment lease financing; deposit products; and securities underwriting and placement, loan syndication and placement, foreign exchange, derivatives, merger and acquisition, and other advisory services. It serves corporate, middle market, and commercial real estate developers and investors. The Consumer Bank segment provides consumer banking products and services related to residential first mortgages, home equity lines and loans, consumer credit cards, and other consumer loans, as well as deposits. The Wealth Management segment offers credit related products, and retirement and savings solutions; and trust and investment management, asset management, and estate planning services to individuals, businesses, governmental institutions, and non-profit entities. It also provides investment and insurance products; low-income housing tax credit corporate fund syndication services; and other specialty financing services. The company was founded in 1971 and is headquartered in Birmingham, Alabama.
NYSE ended the session with Regions Financial Corporation falling 11.39% to $14.60 on Friday while NYSE dropped 1.07% to $15,033.31.
Earnings Per Share
As for profitability, Regions Financial Corporation has a trailing twelve months EPS of $2.35.
PE Ratio
Regions Financial Corporation has a trailing twelve months price to earnings ratio of 6.21. Meaning, the purchaser of the share is investing $6.21 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.91%.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Regions Financial Corporation’s stock is considered to be overbought (>=80).
Yearly Top and Bottom Value
Regions Financial Corporation’s stock is valued at $14.60 at 17:32 EST, way under its 52-week high of $24.33 and above its 52-week low of $13.94.
Moving Average
Regions Financial Corporation’s worth is way under its 50-day moving average of $18.20 and way under its 200-day moving average of $19.33.
More news about Regions Financial Corporation.
9. XTL Biopharmaceuticals Ltd. (XTLB) – -9.85%
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. XTL Biopharmaceuticals Ltd. has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.
NASDAQ ended the session with XTL Biopharmaceuticals Ltd. sliding 9.85% to $0.90 on Friday while NASDAQ fell 1.53% to $12,983.81.
Earnings Per Share
As for profitability, XTL Biopharmaceuticals Ltd. has a trailing twelve months EPS of $-0.48.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -68.88%.
More news about XTL Biopharmaceuticals Ltd..
10. Zions Bancorporation N.A. (ZION) – -9.67%
Zions Bancorporation, National Association provides various banking and related services primarily in the states of Arizona, California, Colorado, Idaho, Nevada, New Mexico, Oregon, Texas, Utah, Washington, and Wyoming. The company offers corporate banking services; commercial banking, including a focus on small- and medium-sized businesses; commercial real estate banking services; municipal and public finance services; retail banking, including residential mortgages; trust services; wealth management and private client banking services; and capital markets products and services. As of December 31, 2020, it operated 422 branches, which included 273 owned and 149 leased. The company was formerly known as ZB, National Association and changed its name to Zions Bancorporation, National Association in September 2018. Zions Bancorporation, National Association was founded in 1873 and is headquartered in Salt Lake City, Utah.
NASDAQ ended the session with Zions Bancorporation N.A. sliding 9.67% to $32.24 on Friday while NASDAQ slid 1.53% to $12,983.81.
Earnings Per Share
As for profitability, Zions Bancorporation N.A. has a trailing twelve months EPS of $5.67.
PE Ratio
Zions Bancorporation N.A. has a trailing twelve months price to earnings ratio of 5.69. Meaning, the purchaser of the share is investing $5.69 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.12%.
More news about Zions Bancorporation N.A..
Stay up to date with our winners and losers daily report
